Danaher Corp., US2358511028

Danaher Corp stock gains support from analyst consensus and recent earnings

Published on 09/15/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher Corp stock carries a Moderate Buy consensus rating as of September 15, 2026, with an average 12-month price target above its current price. The shares recently traded near USD 203, while fundamentals show mid-single-digit revenue growth and an earnings beat in the latest quarter.

Schwarz-Weiß-Reportagefoto eines Forschers am Mikroskop in einem klassischen Diagnostiklabor
Danaher Corp. Diagnostik-Labor US2358511028 in dokumentarischer Schwarzweiß-Reportage mit Forscher am alten Mikroskop, Illustration mit AI erstellt.

Danaher Corp stock (ISIN US2358511028) is trading near USD 203 on the New York Stock Exchange as of the most recent completed session in mid-September 2026, supported by a Moderate Buy analyst consensus and a recent earnings beat that showed mid-single-digit revenue growth year over year.

Analyst consensus and price targets

According to MarketBeat on September 15, 2026, Danaher Corporation (ticker DHR) has a consensus rating of Moderate Buy from 25 analysts, with five rating the shares as hold, eighteen as buy and two as strong buy.

The same overview reports an average 12-month price target of USD 228.91, which stands around USD 25 above the referenced share price of USD 203.44 on that day, implying upside potential of roughly 12.5 percent based on that snapshot.MarketBeat

Recent analyst actions are mixed: Wells Fargo set a neutral rating with a USD 195 target, while UBS initiated coverage with a buy rating and a USD 250 objective, framing a spread of USD 55 between cautious and more optimistic views.MarketBeat

Earnings beat and revenue growth underpin the story

In its most recently reported quarter, Danaher exceeded market expectations on both earnings and revenue, providing a fundamental backdrop for the current analyst stance.

As summarized by MarketBeat, Danaher reported adjusted earnings of USD 1.94 per share in its latest quarter, coming in USD 0.09 above the consensus estimate of USD 1.85 per share.

Quarterly revenue reached USD 6.26 billion, up 5.5 percent year over year, indicating mid-single-digit top-line growth despite a more challenging macro and sector environment.MarketBeat

For investors, this combination of an earnings beat and mid-single-digit revenue growth helps to justify the Moderate Buy consensus and the average target above the prevailing share price, even as some houses such as Wells Fargo remain more cautious on valuation.

Recent price performance and sector jitters

Danaher shares have seen short-term volatility in September as sector sentiment in healthcare and life sciences tools has shifted.

According to Ad-hoc-news in a price-focused update dated September 14, 2026, Danaher Corp stock closed the September 11, 2026 session on the NYSE at USD 200.30, representing a decline of around 1.6 percent from its prior close.

The same report notes that Danaher’s global market capitalization stood at EUR 121.89 billion as of September 13, 2026, corresponding to a euro-denominated share price of EUR 173.40 for that date, with a day-on-day change of minus 0.19 percent, underscoring a softer tone in recent trading.Ad-hoc-news

On a broader basis, Danaher’s market capitalization is reported at around USD 140.7 billion in September 2026, placing the group roughly in the 150s by global ranking and reflecting an 8.55 percent decrease in market cap for 2026 compared with the prior year, according to CompaniesMarketCap.

Sector sentiment has also played a role: TipRanks reported on September 14, 2026 that Danaher stock was slipping amid broader healthcare and life sciences sector jitters tied to interest rate worries and shifting risk appetite, with year-to-date price performance at minus 12.20 percent and a current market cap of USD 140.7 billion.

Technical picture and trading metrics

From a technical perspective, Danaher’s recent moves can be put into context by looking at its moving averages and trend metrics.

Data compiled by Barchart show that over the most recent five-day period the stock price change metric reflects an increase of USD 7.52, equivalent to a gain of 4.15 percent versus its five-day moving average baseline of USD 180.19.

Over a 20-day horizon, the price change stands at USD 16.06, translating into a 9.29 percent increase versus the 20-day moving average of USD 181.07, indicating that the stock has moved back above short-term trend levels in recent sessions.Barchart

At the same time, longer-term metrics highlight a more mixed picture: Barchart’s technical overview lists a 200-day moving average of USD 203.96, implying that the current price near USD 203 is slightly below this longer-term trend mark, while the year-to-date metric shows a decline of 17.50 percent from a starting reference of USD 197.27.Barchart

Stock price and investor takeaways

Per NYSE-linked data cited in the MarketBeat overview, Danaher Corp stock recently opened around USD 203.44 on the NYSE, with the shares trading on the primary US exchange in USD and fluctuating in a 12-month range between a low of USD 160.93 and a high of USD 242.80.MarketBeat

For investors, the key tension lies between a share price that has retreated year to date and sits slightly below the 200-day moving average, and a fundamental profile that still shows revenue growth and an earnings beat, combined with a Moderate Buy analyst consensus and an average target price comfortably above the latest quotation.

Danaher Corp stock key data

  • Company: Danaher Corp
  • ISIN: US2358511028
  • Ticker: DHR
  • Trading venue: NYSE
  • Price (as of September 14, 2026): 203.44 USD
  • Market capitalization: 140.70 billion USD (as of September 14, 2026)
  • Sector / Industry: Health Care / Life Sciences Tools and Services
  • Index membership: S&P 500

More news and analyses on Danaher Corp stock

Disclaimer...

en | US2358511028 | DANAHER CORP. | boerse | 70104429 | bgmi